Project Grant K22CA299598
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $193K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) totaling $138,489 will support research to develop a "Methyl Arginine Targeting Chimera for the Lysosomal Degradation of Intracellular Proteins". The project aims to characterize a novel approach to targeted protein degradation that utilizes lysosomal pathways, rather than the traditional proteasomal system, to eliminate disease-causing proteins. This innovative research has the...
- This federal Project Grant award of $2,579,971.00, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to investigate the molecular drivers and therapeutic susceptibilities of lineage state transitions in metastatic prostate cancer. The 5-year project, awarded to the University of Wisconsin - Madison, aims to study the regulation of the androgen receptor transcriptional state in distinct tumor niches, evaluate the role of genomic...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $509,246 to the Regents of the University of Michigan to conduct research on early drivers of prostate cancer lineage plasticity. The project aims to identify key transcriptional regulators that repress androgen receptor signaling and promote alternate differentiation programs in prostate cancer, with the goal of preventing lineage plasticity and disease progression. By...
- This $150,104 federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to Yale University supports research to determine the regulatory role of dose-sensitive 5-methylcytosine (m5C) modifications on mRNA translation initiation and their impact on cancer. The project aims to screen approximately 35,000 human 5' untranslated regions (5'-UTRs) for m5C installation by the methyltransferases NSUN2 and NSUN6, and quantify ribosome recruitment to these...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $185,760 to The Regents of the University of California, San Francisco (UCSF) to develop a novel combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC). The project aims to co-deliver an antibody-drug conjugate (MMAE) and an alpha particle radioactive isotope (Actinium-225) directly to cancer cells, creating a synergistic effect to combat...
- The National Cancer Institute awarded a $571,271 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston. The goal of this 5-year research project is to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer, an aggressive form of the disease with limited treatment options. The project will explore using a small molecule drug conjugate that targets the prostate-specific membrane...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to define key components of the PRMT5 axis that impair cell viability upon PRMT5 inhibition and identify pathways that can restore viability in MTAP-deleted cancer cells. The $442,089 award to Yale University will leverage a genome-scale CRISPR activation platform to identify genes that modulate sensitivity to PRMT5 pathway inhibition. The research aims to...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support research at the Weill Medical College of Cornell University to investigate the role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer. The $683,979 award, effective June 1, 2025 through April 30, 2030, will fund a multi-institutional collaborative effort to define the propensity of prostate cancers harboring SPOP mutations to progress to specific subtypes...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop new chemical probes capable of effectively targeting the "undruggable" c-MYC protein, which is implicated in driving the progression of castration-resistant prostate cancer (CRPC). The $177,209 award to Temple University aims to apply the university's Fluorine-Thiol Displacement Reaction (FTDR) stapling technology to rationally design c-MYC targeted peptide...
- This federal Project Grant award of $460,740.00 was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to Yale University. The project aims to develop novel quantitative experimental and computational methods for studying continuous phenotypic transitions in cellular states, with applications across ovarian aging, cardiovascular disease, and hormone-dependent cancers. Key objectives include using...